DBF2 Antibody

What is DBF2 and what cellular functions does it regulate?

DBF2 is a conserved NDR (nuclear Dbf2-related) protein kinase that plays essential roles in multiple cellular processes. Its primary functions include:

• Regulation of cell cycle progression, particularly during late mitosis (anaphase/telophase)

• Control of cytokinesis through interaction with and phosphorylation of proteins like Hof1

• Association with transcriptional regulation via the CCR4 complex

• In filamentous fungi, DBF2 links the Hippo and glycogen metabolism pathways, affecting mitosis, glycogen biosynthesis, and conidiation

The kinase activity of DBF2 is cell cycle-regulated, with peak activity occurring during late mitosis. Notably, DBF2 exists in both phosphorylated and non-phosphorylated forms, with the non-phosphorylated form believed to contain the active kinase activity . Studies indicate DBF2 functions downstream of other mitotic exit network (MEN) components including Tem1 and Cdc15 .

What are the key considerations for selecting a DBF2 antibody?

When selecting a DBF2 antibody for research, consider these critical factors:

• Epitope specificity: Due to sequence similarities with other NDR kinases (e.g., 52.8% similarity between the catalytic domains of DBF2 and COT-1 in N. crassa), ensure the antibody targets unique epitopes . Monospecific clonal antibodies targeting carefully selected linear epitopes of 4-7 amino acids can provide higher specificity .

• Validation in multiple assays: Verify the antibody has been validated in your specific application (Western blot, immunoprecipitation, immunohistochemistry). An ideal antibody would be characterized across multiple assays to ensure consistent performance .

• Species reactivity: Confirm compatibility with your model system, as DBF2 functions have been studied across various organisms including S. cerevisiae, N. crassa, and others .

• Phosphorylation state detection: If studying DBF2 activation, determine whether the antibody can distinguish between phosphorylated and non-phosphorylated forms, which correlate with different activity states .

Using antibodies with inadequate characterization can lead to non-reproducible results, with estimates suggesting ~50% of commercial antibodies fail to meet basic characterization standards .

How can I effectively use DBF2 antibodies for immunoprecipitation and kinase assays?

Immunoprecipitation with DBF2 antibodies allows isolation of the kinase and assessment of its activity. A methodological approach includes:

• Cell lysis: Use buffers that preserve kinase activity, typically containing protease inhibitors, phosphatase inhibitors, and mild detergents.

• Immunoprecipitation protocol:

  • Incubate cell extracts with DBF2 antibody (5-10 μg)

  • Add protein A/G beads and rotate at 4°C for 2-4 hours

  • Wash extensively with lysis buffer followed by kinase buffer washes

• Kinase activity assessment:

  • Incubate immunoprecipitates with an artificial substrate like histone H1

  • Include ATP (typically 50-100 μM) and radioactive [γ-³²P]-ATP

  • Analyze phosphorylation by SDS-PAGE and autoradiography or phosphorimaging

Research has shown that DBF2 immunoprecipitated from wild-type cells exhibits varying levels of kinase activity depending on cell cycle stage, with highest activity during late mitosis. When studying DBF2 function, it's important to include controls from mutant strains (e.g., tem1-3, cdc15-2, cdc5-1, mob1-77) to validate pathway-specific effects .

What are the optimal conditions for using DBF2 antibodies in Western blot analysis?

For successful Western blot detection of DBF2:

• Sample preparation:

  • Include phosphatase inhibitors to preserve phosphorylation states

  • Use freshly prepared lysates when possible to minimize degradation

  • For cell cycle studies, synchronize cells and collect at specific timepoints

• Gel electrophoresis conditions:

  • 8% SDS-PAGE gels provide good resolution for DBF2 (~60-70 kDa)

  • For detecting phosphorylation shifts, consider using Phos-tag gels

• Transfer and blotting:

  • Transfer at 100V for 1 hour or 30V overnight at 4°C

  • Block with 5% non-fat milk or BSA in TBST (phospho-specific antibodies typically require BSA)

  • Incubate with primary antibody (1:1000-1:5000 dilution, optimize for each antibody)

  • Use secondary antibodies with appropriate species specificity

• Detection considerations:

  • DBF2 often appears as multiple bands due to phosphorylation states

  • When studying DBF2 phosphorylation, dephosphorylated DBF2 appears with the same cell cycle timing as kinase activity

Include positive controls (e.g., tagged DBF2) and negative controls (e.g., dbf2 deletion strains) to verify antibody specificity .

How can I distinguish between DBF2 and related NDR kinases when using antibodies?

Distinguishing between DBF2 and related NDR kinases requires careful experimental design:

• Epitope selection strategies:

  • Target unique regions outside the conserved catalytic domain

  • Use bioinformatic analysis to identify DBF2-specific sequences

  • Consider using the DB Biotech EDAS (Epitope Design and Analysis System) approach to identify linear epitopes accessible under various conditions

• Validation in knockout/mutant models:

  • Always test antibodies in dbf2 deletion strains to confirm specificity

  • Create control panels including related kinases (e.g., Dbf20 in yeast, COT-1 in N. crassa)

  • Use peptide competition assays with DBF2-specific and related kinase peptides

• Cross-reactivity assessment:

  • Perform immunoprecipitation followed by mass spectrometry to identify all captured proteins

  • Use recombinant proteins of DBF2 and related kinases to quantify binding specificity

• Signal verification:

  • Correlate antibody signals with known cell cycle-dependent regulation patterns of DBF2

  • Verify phosphorylation-dependent mobility shifts are consistent with DBF2's known regulation

Research has shown significant sequence similarities between related NDR kinases (e.g., 52.8% similarity between catalytic domains of DBF2 and COT-1 in N. crassa) , making antibody specificity validation critical.

What methods can be used to study DBF2 phosphorylation states and their functional significance?

Studying DBF2 phosphorylation requires specialized approaches:

• Phospho-specific antibodies:

  • Use antibodies that specifically recognize phosphorylated residues

  • Validate using phosphatase treatment of samples to confirm specificity

  • Consider developing custom phospho-specific antibodies for key regulatory sites

• Phosphorylation site mapping:

  • Immunoprecipitate DBF2 followed by mass spectrometry analysis

  • Use phospho-peptide enrichment techniques (TiO₂, IMAC) to improve detection

  • Compare phosphorylation patterns across cell cycle stages

• Functional analysis of phosphorylation sites:

  • Generate phospho-mimetic (S→E) and phospho-deficient (S→A) mutants

  • Analyze the effect of these mutations on:

    • Kinase activity (using in vitro kinase assays)

    • Protein-protein interactions (using co-immunoprecipitation)

    • Cellular phenotypes (using microscopy for cell cycle/cytokinesis defects)

• Kinetics of phosphorylation changes:

  • Synchronize cells and collect at defined cell cycle points

  • Use quantitative Western blotting or mass spectrometry to track changes

  • Correlate with kinase activity measurements

Research has demonstrated that DBF2 itself is a phosphoprotein, and significantly, the dephosphorylated form appears with the same cell cycle timing as kinase activity, suggesting dephosphorylation plays a role in the activation mechanism .

How can I effectively study DBF2 interactions with binding partners like MOB1 using antibodies?

To study DBF2-MOB1 or other protein interactions:

• Co-immunoprecipitation approaches:

  • Use DBF2 antibody to pull down complexes, then probe for interacting partners

  • Perform reciprocal experiments using antibodies against suspected binding partners

  • Include negative controls using unrelated antibodies (e.g., LexA antibody has been used as a control)

• Proximity-based detection methods:

  • Consider proximity ligation assays (PLA) for in situ detection of interactions

  • Use FRET or BiFC for live-cell interaction studies if fluorescent tagging is possible

• Binding domain mapping:

  • Use truncated protein constructs to identify interaction domains

  • Data indicates that MOB1(9-314) can interact with both full-length DBF2(1-561) and truncated DBF2(205-561)

• Competition assays:

  • Use purified recombinant domains to compete with full-length protein interactions

  • Quantify interaction strength changes under different conditions

Research has demonstrated that interaction between DBF2 and MOB1 can be detected through two-hybrid assays, with quantitative measurements showing that LexA-MOB1(9-314) interaction with B42-DBF2(1-561) produces significantly higher beta-galactosidase activity (6,700 units) compared to controls (81 units for B42 alone) .

What techniques can be used to study the DBF2 association with the CCR4 transcriptional complex?

To investigate DBF2's role in the CCR4 complex:

• Sequential immunoprecipitation:

  • First immunoprecipitate with CCR4 antibody

  • Elute under mild conditions and perform a second immunoprecipitation with DBF2 antibody

  • Analyze resulting complexes by Western blot or mass spectrometry

• Chromatin immunoprecipitation (ChIP):

  • Use DBF2 antibodies for ChIP to identify potential DNA binding sites

  • Compare with CCR4 ChIP profiles to identify overlapping targets

  • Perform sequential ChIP (ChIP-reChIP) to confirm co-occupancy

• Complex purification:

  • Combine chromatographic techniques with immunoaffinity purification

  • Use tagged versions of DBF2 or CCR4 complex components for efficient isolation

  • Analyze complex composition under different cellular conditions

• Functional assays:

  • Measure CCR4-dependent transcriptional activity in DBF2 mutants

  • Assess DBF2 kinase activity in CCR4 immunoprecipitates using artificial substrates like histone H1

  • Use kinase-dead DBF2 mutants to distinguish structural from enzymatic roles

Research has demonstrated that B42-DBF2 co-immunoprecipitates with CCR4 and CAF1, and that DBF2 contributes kinase activity to the CCR4 complex. Additionally, dbf2 disruption results in phenotypes similar to strains deficient for CCR4 or CAF1, indicating functional connections between these components .

How can I apply AI-based approaches to improve DBF2 antibody specificity and experimental design?

Emerging AI technologies offer new possibilities for antibody research:

• Epitope prediction and optimization:

  • Use RFdiffusion or similar AI tools to design antibody binding loops with higher specificity for DBF2

  • Apply computational modeling to identify unique DBF2 epitopes not present in related kinases

  • Predict structural changes in DBF2 across phosphorylation states to target state-specific epitopes

• Experimental design optimization:

  • Use machine learning to identify optimal buffer conditions and protocols based on published data

  • Apply bioinformatics-informed modeling similar to approaches used in antibody specificity inference

  • Develop predictive models for antibody cross-reactivity based on sequence similarity analysis

• AI-assisted validation:

  • Use image analysis algorithms to quantify co-localization in microscopy experiments

  • Apply machine learning to detect subtle phenotypic changes in DBF2 mutant studies

  • Use natural language processing to systematically review and integrate findings from DBF2 literature

• Novel antibody formats:

  • Explore single chain variable fragments (scFvs) designed with RFdiffusion for enhanced specificity

  • Consider nanobodies as alternatives for detecting specific DBF2 conformations or complexes

Recent advances in antibody design using RFdiffusion demonstrate the potential to create human-like antibodies with customized binding properties and improved specificity , which could be applied to generate better DBF2-specific reagents.

What methods can be used to study the dynamic localization of DBF2 during cell cycle progression?

To track DBF2 localization throughout the cell cycle:

• Fixed-cell immunofluorescence microscopy:

  • Optimize fixation conditions to preserve epitope accessibility while maintaining cellular structures

  • Use cell cycle markers (e.g., spindle morphology, DNA content) to identify specific cell cycle stages

  • Consider super-resolution techniques (STORM, STED) for precise localization

• Live-cell imaging approaches:

  • If direct antibody labeling isn't possible, correlate antibody staining patterns with fluorescently tagged DBF2

  • Use synchronized cells to track changes over the cell cycle

  • Combine with probes for cellular structures (e.g., septins, actomyosin ring) to analyze co-localization

• Quantitative analysis methods:

  • Develop intensity profiles across cellular compartments

  • Track the nuclear/cytoplasmic ratio of DBF2 through the cell cycle

  • Correlate localization changes with activity measurements

• Cell cycle perturbation experiments:

  • Use temperature-sensitive mutants (tem1-3, cdc15-2, cdc5-1) to arrest cells at specific stages

  • Analyze DBF2 localization changes upon release from arrest

  • Compare with known localization patterns of interacting partners (MOB1, septins)

Research has shown that DBF2 is predominantly localized to the nucleus in N. crassa , while in yeast its localization may change during the cell cycle. Understanding these dynamics is essential for interpreting antibody-based detection methods.

What controls and validation approaches are essential when using DBF2 antibodies?

Comprehensive validation includes:

• Genetic controls:

  • dbf2 deletion/knockout strains as negative controls

  • Strains with tagged DBF2 (e.g., FHH-DBF2) as positive controls

  • Temperature-sensitive mutants to correlate phenotypes with antibody signals

• Biochemical validation:

  • Peptide competition assays to confirm epitope specificity

  • Immunodepletion to verify complete removal of the target protein

  • Western blots showing expected molecular weight and cell-cycle dependent changes

• Cross-validation with multiple antibodies:

  • Use antibodies targeting different epitopes and compare staining patterns

  • Correlate signals from commercial and custom antibodies

  • Compare monoclonal and polyclonal antibody results

• Functional correlation:

  • Verify that antibody signals correlate with known DBF2 activity patterns

  • Confirm decreased signals in conditions known to reduce DBF2 expression/activity

  • Correlate with phenotypic observations (e.g., cell cycle defects)

Studies have shown that improper antibody validation can lead to irreproducible results, with estimated financial losses of $0.4-1.8 billion per year in the United States alone due to inadequately characterized antibodies .

What are common pitfalls when using DBF2 antibodies and how can they be addressed?

Common challenges and solutions include:

• Cross-reactivity with related kinases:

  • Problem: DBF2 shares significant sequence similarity with other NDR kinases

  • Solution: Pre-absorb antibodies against recombinant related kinases; validate in knockout models

• Cell cycle-dependent epitope masking:

  • Problem: Phosphorylation or protein interactions may mask epitopes at certain cell cycle stages

  • Solution: Use multiple antibodies targeting different regions; compare with tagged protein detection

• Low signal-to-noise ratio:

  • Problem: DBF2's regulated expression can result in low abundance at certain stages

  • Solution: Optimize extraction conditions; consider signal amplification methods; synchronize cells

• Inconsistent immunoprecipitation efficiency:

  • Problem: Complex formation may interfere with antibody binding

  • Solution: Test multiple antibodies; optimize buffer conditions; use mild detergents to preserve interactions

• Phosphorylation state detection challenges:

  • Problem: Distinguishing between phosphorylated and non-phosphorylated forms

  • Solution: Use phospho-specific antibodies; include phosphatase treatments as controls; use mobility shift assays

Research has demonstrated that DBF2 exists in both phosphorylated and non-phosphorylated forms, with the non-phosphorylated form correlating with kinase activity , making accurate detection of these states critical for functional studies.

How are DBF2 antibodies being used to understand the relationship between cell cycle regulation and transcriptional control?

Current research approaches include:

• Integrated cell cycle and transcriptome analysis:

  • Synchronize cells and collect at defined timepoints

  • Use DBF2 antibodies to immunoprecipitate associated complexes

  • Perform RNA-seq or ChIP-seq to identify regulated genes

  • Correlate with DBF2 kinase activity measurements

• Studies of CCR4 complex regulation:

  • Investigate how DBF2 phosphorylation of CCR4 complex components affects function

  • Analyze transcriptional changes in dbf2 mutants versus ccr4 or caf1 mutants

  • Identify substrates of DBF2 within transcriptional machinery

• Mechanistic investigations:

  • Study how cell cycle signals are transmitted to the transcriptional apparatus via DBF2

  • Analyze the timing of DBF2 recruitment to chromatin relative to cell cycle progression

  • Investigate whether DBF2 kinase activity directly regulates transcription factors

• Multi-omics approaches:

  • Integrate phosphoproteomics, transcriptomics, and chromatin structure analyses

  • Map the network of DBF2-dependent phosphorylation events affecting transcription

  • Correlate with cellular phenotypes in wild-type and mutant strains

Research has shown that DBF2 is physically associated with the CCR4 transcriptional complex, and that mutations in DBF2, CCR4, and CAF1 result in similar phenotypes, suggesting a functional link between cell cycle regulation and transcriptional control .

What role do DBF2 antibodies play in understanding evolutionary conservation of NDR kinase function across species?

Investigating evolutionary conservation requires:

• Comparative studies across model organisms:

  • Use DBF2 antibodies with confirmed cross-species reactivity

  • Compare localization, activity patterns, and protein interactions across species

  • Identify conserved versus divergent functions through immunoprecipitation studies

• Complementation analyses:

  • Express DBF2 from different species in model organisms

  • Use antibodies to confirm expression and analyze localization/interactions

  • Assess functional conservation through phenotypic rescue experiments

• Conservation of regulatory mechanisms:

  • Compare phosphorylation patterns of DBF2 orthologs across species

  • Analyze conservation of interaction partners (e.g., MOB1, CCR4)

  • Study timing of activation relative to cell cycle events

• Structure-function studies:

  • Use antibodies recognizing conserved epitopes to study core functions

  • Employ species-specific antibodies to investigate specialized roles

  • Correlate structural conservation with functional data

Research has revealed conservation of DBF2 function across diverse fungi, from budding yeast to filamentous fungi like N. crassa, where DBF2 serves as a link between Hippo and glycogen metabolism pathways . Understanding this evolutionary conservation provides insight into fundamental cellular regulatory mechanisms.